Senolytics Clinical Trials in 2026: What You Need to Know

The Rise of Senolytic Medicine

The field of senolytics has rapidly evolved from a theoretical concept to one of the most actively researched areas in longevity science. Senolytic drugs are designed to selectively eliminate senescent cells — aged, damaged cells that have stopped dividing but refuse to die. These so-called zombie cells accumulate throughout the body with age and may contribute to chronic inflammation, tissue dysfunction, and age-related diseases.

As of 2026, multiple clinical trials are testing senolytic compounds in humans, representing a significant milestone in the quest to translate laboratory discoveries into potential therapies. Understanding where these trials stand may help provide insight into the future of aging research.

Understanding Senescent Cells and Why They Matter

Before diving into the clinical trial landscape, it is important to understand why senescent cells have become such a focal point in aging research.

When cells experience significant damage — from DNA mutations, telomere shortening, oxidative stress, or other insults — they may enter a state called cellular senescence. In this state, cells stop dividing permanently but remain metabolically active. While this process may serve as a protective mechanism against cancer in younger organisms, the accumulation of senescent cells over time appears to be problematic.

Senescent cells secrete a complex mixture of inflammatory molecules, growth factors, and enzymes collectively known as the senescence-associated secretory phenotype (SASP). Research suggests that SASP may contribute to chronic low-grade inflammation, sometimes called inflammaging, which has been linked to numerous age-related conditions.

Studies in animal models have demonstrated that selectively removing senescent cells may extend healthspan and lifespan. A landmark 2016 study published in Nature showed that clearing senescent cells in mice extended median lifespan and improved physical function. These findings provided the foundation for human clinical trials.

Major Senolytics Clinical Trials in 2026

Dasatinib Plus Quercetin (D+Q) Trials

The combination of dasatinib, an FDA-approved cancer drug, and quercetin, a natural flavonoid, was one of the first senolytic combinations identified by researchers at Mayo Clinic. This combination remains the most extensively studied senolytic approach in human trials.

A pioneering 2019 study published in EBioMedicine provided preliminary evidence that D+Q could reduce senescent cell burden in humans with idiopathic pulmonary fibrosis. The study measured senescent cell markers in skin and blood, finding decreases in several senescence-associated markers after treatment.

As of 2026, several expanded clinical trials are evaluating D+Q in various contexts:

• Alzheimer’s Disease: The SToMP-AD trial at Wake Forest University has been investigating whether D+Q can reduce senescent cell burden in the brain and potentially slow cognitive decline in early-stage Alzheimer’s patients.
• Chronic Kidney Disease: Researchers at Mayo Clinic have been conducting trials examining whether intermittent D+Q administration may improve kidney function markers in patients with diabetic kidney disease.
• Frailty in Older Adults: Multiple institutions are studying whether D+Q may improve physical function and reduce frailty markers in elderly populations.

Unity Biotechnology Pipeline

Unity Biotechnology, one of the first companies dedicated to developing senolytic medicines, has been advancing several drug candidates through clinical development. After early setbacks with their first compound UBX0101 for knee osteoarthritis, the company pivoted to focus on ophthalmology and other indications.

Their pipeline includes compounds targeting specific senescent cell populations in different tissues. The approach reflects an evolving understanding that senolytic treatments may need to be tailored to specific tissues and disease contexts rather than applied systemically.

Fisetin Clinical Trials

Fisetin, a natural flavonoid found in strawberries and other fruits, has shown senolytic properties in preclinical studies. The AFFIRM-LITE trial and related studies have been evaluating fisetin’s potential as a senolytic in human subjects.

Research published in EBioMedicine demonstrated that fisetin could reduce senescent cell markers in aged mice. Human trials are now examining whether similar effects may occur in people, with endpoints including changes in inflammatory markers, physical function, and biological age measurements.

Novel Senolytic Approaches

Beyond the established compounds, several innovative senolytic strategies are entering clinical evaluation:

• Chimeric antigen receptor (CAR) T-cell therapy for senescent cells: Researchers have engineered immune cells to specifically target and destroy senescent cells, showing promise in preclinical models.
• Senolytic vaccines: Scientists have explored the possibility of training the immune system to recognize and clear senescent cells, potentially providing long-lasting senolytic effects.
• Targeted drug delivery systems: Nanoparticle-based approaches are being developed to deliver senolytic drugs specifically to senescent cells, potentially reducing off-target effects.

Key Findings from Completed Trials

Several completed or interim analyses from senolytic trials have provided valuable data:

Safety Profiles

One of the most encouraging findings from early clinical trials is the generally acceptable safety profile of senolytic treatments when administered intermittently. Unlike many drugs that require daily dosing, senolytics are typically given in short courses — often just a few days per month — because senescent cells accumulate slowly.

A 2019 pilot study found that D+Q was well tolerated in patients with idiopathic pulmonary fibrosis, with the most common side effects being mild and transient. However, researchers note that larger and longer studies are needed to fully characterize the safety profile.

Biological Markers

Several trials have reported changes in biological markers associated with cellular senescence and inflammation. These include:

• Reduced levels of SASP factors such as IL-6 and TNF-alpha
• Decreased expression of senescence markers p16INK4a and p21
• Improvements in some measures of physical function

However, it is important to note that changes in biomarkers do not necessarily translate to clinical benefits, and researchers caution against over-interpreting preliminary results.

Functional Outcomes

Some trials have reported improvements in functional measures, including walking speed, chair stand tests, and grip strength in older adults. While these findings are preliminary, they suggest that reducing senescent cell burden may have measurable effects on physical function.

Challenges in Senolytic Clinical Development

Measuring Success

One of the significant challenges in senolytic clinical trials is defining and measuring success. Unlike trials for specific diseases with clear endpoints, aging-related trials must contend with the complexity of measuring biological aging itself.

Researchers have employed various approaches, including epigenetic clocks, inflammatory biomarker panels, and functional assessments. The field is working to standardize these measurements to enable better comparison across trials.

Patient Selection

Determining which patients may benefit most from senolytic therapy is another ongoing challenge. Senescent cell burden varies significantly between individuals of the same age, and current methods for measuring this burden are not yet standardized for clinical use.

Dosing and Timing

Optimizing dosing schedules for senolytics is complex. Because these drugs work by eliminating cells rather than modulating ongoing processes, the traditional pharmacological approach of steady-state dosing does not apply. Researchers are working to determine the optimal frequency and duration of senolytic courses.

The Regulatory Landscape

The FDA does not currently recognize aging as a treatable condition, which presents challenges for senolytic drug development. Most clinical trials are therefore designed around specific age-related diseases rather than aging itself.

However, there are signs of evolving regulatory thinking. The Targeting Aging with Metformin (TAME) trial has helped establish precedents for studying aging-related endpoints. The growing body of evidence linking senescent cells to specific diseases may also facilitate regulatory pathways for senolytic therapies.

What This Means for the Future

The current landscape of senolytic clinical trials represents a pivotal moment in aging research. While no senolytic therapy has yet been approved for any age-related indication, the volume and diversity of ongoing trials suggest that the field is maturing rapidly.

Research suggests several possible trajectories for the near future:

• Tissue-specific senolytics: Treatments may be tailored to target senescent cells in specific tissues, potentially improving efficacy and reducing side effects.
• Combination approaches: Senolytics may be combined with other anti-aging interventions, such as NAD+ boosters or rapamycin analogs, for synergistic effects.
• Preventive applications: If proven safe and effective, senolytics might eventually be used preventively in healthy aging populations rather than only in disease contexts.

The Bottom Line

Senolytics represent one of the most promising approaches in the quest to address biological aging. The transition from laboratory discoveries to human clinical trials marks an important step forward, though significant work remains before these treatments may become widely available.

The results from ongoing trials in 2026 and beyond will be critical in determining whether the dramatic benefits observed in animal models can be replicated in humans. For now, the research community urges caution against self-experimentation with senolytic compounds outside of clinical trial settings.

As with all emerging therapies, individuals interested in senolytics should consult their healthcare provider and consider participating in clinical trials through established research institutions.